In Vivo Recovery and Survival Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution

Completed · Not applicable

Conditions studied: Healthy Volunteers

In brief

The purpose of this study is to evaluate the quality of platelets collected on the Trima Accel system after storage for 5 days in a Platelet Additive Solution (PAS), called InterSol.

Key facts

Study ID

NCT03097289

Run by

Terumo BCT

People needed

33

Starts

2017-07-26

Expected to finish

2017-11-24

Last updated by the study team

2018-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Age 18 years or older
• Normal health status as per AABB criteria for a healthy donor
• Able to commit to the study schedule
• Meets the inclusion criteria defined by the Blood Center for an apheresis platelet with PAS collection on the Trima Accel system. These criteria are based on FDA Regulations and AABB standards. Note: Participants who are deferred from volunteer community donations because of travel restrictions, piercings, or tattoos may participate in the study, as products are not transfused
• Participants of child-bearing potential (either male or female) must agree to use an effective method of contraception during the course of the study
• Female of childbearing potential must be willing to take a pregnancy test prior to infusion of radiolabeled platelets
• Has given written informed consent

You may not qualify if…

• Previously received radiation therapy
• Has been diagnosed with a platelet disorder (ie, platelet dysfunction)
• Already participated in 4 research studies involving radioisotopes within the contemporaneous calendar-year
• Pregnant or nursing females
• Participation currently, or within the last 12 months, in another investigational trial that would potentially interfere with the analysis of this investigation
• History of known hypersensitivity to indium or chromium
• Treatment with aspirin or aspirin containing medications within 7 days of apheresis or treatment with non-steroidal anti inflammatory drugs (NSAID), anti-platelet agents or other drugs affecting platelet viability within 3 days of apheresis (eg, ibuprofen or other NSAIDs)

Where it is running

• Hoxworth Blood Center — Cincinnati, Ohio, United States
• BloodCenter of Wisconsin — Milwaukee, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.